• Sienna slumps as acne asset flunks phase 3 trials fiercebiotech
    July 31, 2018
    Sienna Biopharmaceuticals’ acne candidate SNA-001 has comprehensively failed two phase 3 trials. The addition of the silver particle treatment to laser light therapy failed to improve outcomes against three key endpoints.....
PharmaSources Customer Service